Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344916 | 1.00 | NR1H2 (0.59) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL344915 | 1.00 | NR1H2 (0.59) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2071987 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31421589 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31421369 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7448268 | 0.93 | NR1H2 (0.52) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL515486 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL514696 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL621267 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16863978 | 0.90 | NR1H2 (0.58) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | NEUSCO BIOTECH LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-6809108-B1 | SELECTIVE MUSCARINIC M3 RECEPTOR ANTAGONTS; REDUCED SIDE EFFECTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20040204369-A1 | Novel amide derivatives | MSD K.K. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1213281-B1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-6262078-B1 | Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain | SYNTEX (U.S.A.) LLC | 2001-07-17 | — | — | US | disclosed |
| US-6110937-A | A SODIUM CHANNEL BLOCKER TREATING AS LOCAL ANESTHETICS AND IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | SYNTEX USA, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0869119-A1 | Phenoxymethyl piperidine derivatives being sodium channle blockers | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-07 | — | — | EP | disclosed |
| CN-1194977-A | Phenoxymethyl piperidine derivatives | HOFFMANN LA ROCHE (CH) | 1998-10-07 | — | — | CN | disclosed |
| CN-1076690-A | SULFONAMIDOCARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 1993-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204369-A1 | Novel amide derivatives | CHRM3, CHRM1, CHRM2 | NR1H2 77/4885MEN1 490/4885ALDH1A1 1744/4885 |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | NR1H2 1118/4885MEN1 4166/4885ALDH1A1 2038/4885 |
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | NR1H2 559/4885MEN1 4297/4885ALDH1A1 23/4885 |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | CHEK1, CHEK2, CCNK | NR1H2 3014/4885MEN1 2942/4885ALDH1A1 2597/4885 |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | NR1H2 473/4885MEN1 3609/4885ALDH1A1 1571/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | NR1H2 3190/4885MEN1 4413/4885ALDH1A1 4311/4885 |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | LPAR1, PLA2R1, LPAR2 | NR1H2 57/4885MEN1 4367/4885ALDH1A1 1113/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | NR1H2 308/4885MEN1 2043/4885ALDH1A1 1002/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | NR1H2 1112/4885MEN1 3022/4885ALDH1A1 2433/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | NR1H2 450/4885MEN1 2352/4885ALDH1A1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.